CD4 and AIDS: In addition, SMART, a randomized trial, demonstrated that patients who deferred ART until their CD4 cell counts dropped to <250 cells/mm3 had a higher risk of AIDS- and non-AIDS-related events than those who initiated therapy immediately [13].